MA53329A - Méthodes de traitement de l'épilepsie - Google Patents
Méthodes de traitement de l'épilepsieInfo
- Publication number
- MA53329A MA53329A MA053329A MA53329A MA53329A MA 53329 A MA53329 A MA 53329A MA 053329 A MA053329 A MA 053329A MA 53329 A MA53329 A MA 53329A MA 53329 A MA53329 A MA 53329A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- epilepsy treatment
- epilepsy
- methods
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53329A true MA53329A (fr) | 2022-03-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053329A MA53329A (fr) | 2018-07-27 | 2019-07-26 | Méthodes de traitement de l'épilepsie |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| EP3999570A1 (en) * | 2019-07-18 | 2022-05-25 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ATE199829T1 (de) * | 1994-06-03 | 2001-04-15 | Thejmde Trust | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| DK3261640T3 (da) * | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000196A1 (es) | 2021-12-31 |
| CA3106031A1 (en) | 2020-01-30 |
| WO2020023923A1 (en) | 2020-01-30 |
| EP3829558C0 (en) | 2024-07-03 |
| SG11202100682YA (en) | 2021-02-25 |
| MX2021000987A (es) | 2021-06-15 |
| ES2988130T3 (es) | 2024-11-19 |
| IL280128A (en) | 2021-03-01 |
| BR112021001135A2 (pt) | 2021-04-20 |
| KR20210061332A (ko) | 2021-05-27 |
| US12558326B2 (en) | 2026-02-24 |
| CO2021002087A2 (es) | 2021-04-30 |
| US20200030260A1 (en) | 2020-01-30 |
| EP3829558A1 (en) | 2021-06-09 |
| CR20210095A (es) | 2021-06-01 |
| PH12021550176A1 (en) | 2021-10-11 |
| EA202190369A1 (ru) | 2021-06-10 |
| CN112930175A (zh) | 2021-06-08 |
| JP2021530541A (ja) | 2021-11-11 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558B1 (en) | 2024-07-03 |
| AU2019310600A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3813808A4 (en) | SUBSTANCE ABUSE TREATMENT PROCEDURES | |
| EP3645121A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| EP3813647A4 (en) | MULTIMODAL STIMULATION FOR TREMOR TREATMENT | |
| MA45192A (fr) | Traitement d'association | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3813806A4 (en) | METHODS OF TREATMENT OF MITOCHONDRIAL DYSFUNCTIONS | |
| EP3291815A4 (en) | METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE | |
| EP3946345A4 (en) | METHODS OF TREATMENT OF NEUROPATHIC PAIN | |
| EP3285776A4 (en) | METHOD FOR TREATING BACTERIAL INFECTIONS | |
| EP3625971A4 (en) | SPATIAL AUDIO PROCESSING | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| MA54860A (fr) | Méthodes de traitement du myélome multiple | |
| EP3775263A4 (en) | COMPOSITIONS AND METHODS OF TREATING ACNE | |
| MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
| EP3773633A4 (en) | METHODS OF TREATMENT OF GLIOBLASTOMA | |
| EP3454793A4 (en) | TREATMENT COILS FOR ANEURYSMS | |
| EP3634422A4 (en) | METHOD FOR TREATMENT OF LEUCODYSTROPHIES | |
| EP3840752A4 (en) | PLATELET COUNT AGNOSTIC METHODS FOR TREATMENT OF MYELOFIBROSIS | |
| EP3393468A4 (en) | METHOD FOR TREATING AN IMMUNE WEAKNESS | |
| EP3599983A4 (en) | ENDOSCOPES AND TREATMENT PROCEDURES | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3383857A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| EP3852816A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3787625A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3873528A4 (en) | Rasopathy treatment |